Therapeutic Group

Indication Dosage

Obinutuzumab is a medication primarily indicated for the treatment of certain types of blood cancers, specifically chronic lymphocytic leukemia (CLL) and follicular lymphoma. It is used in combination with other chemotherapy agents and is prescribed to patients who require therapy for these specific malignancies. Obinutuzumab works by targeting and binding to specific proteins in cancer cells, thereby helping to slow down the progression of the disease and improve overall treatment outcomes.

Chronic Lymphocytic Leukemia (CLL) In Combination With Chlorambucil: 

By IV Infusion: 

Adult: To Be Administered During Six 28-day Treatment Cycles As Follows: 

• Cycle 1 (loading Doses): Day 1: 100 Mg, Day 2: 900 Mg, Day 8: 1000 Mg, Day 15: 1000 Mg 
• Cycles 2-6: Day 1: 1000 Mg 

Follicular Lymphoma (fl), In Combination With Bendamustine Followed Monotherapy: 

By IV Infusion: 

Adult: To Be Administered During Six 28-day Treatment Cycles As Follows: 

• Cycle 1 (loading Doses): Day 1: 1000 Mg, Day 2: 1000 Mg, Day 8: 1000 Mg, Day 15: 1000 Mg 
• Cycles 2-6 Or 2-8: Day 1: 1000 Mg Followed By Monotherapy: 1000 Mg Every 2 Months For Up To Two Years

Content

Pregnancy

Positive Evidence Of Risk: Avoid

Stability

Contra Indications

Precautions

Lactation

Side Effects